Joint Initiative in Vaccine Economics (JIVE) Project, Phase 3

简介(申请人提供)：背景。疫苗是最具成本效益的公共卫生干预措施之一，但最近其成本大幅增加。需要正在进行的疫苗经济研究为国家政策建议以及州免疫规划管理者、健康保险公司和提供者的方案选择提供信息。明确的目标。我们请求继续支持疫苗经济学联合倡议(JIVE)项目，该项目支持哈佛大学和疾控中心研究人员的研究。我们会进行四项研究。研究1将解决RFA的第一个目标，即估计将联合疫苗引入儿科实践的相关成本。研究2将涉及RFA的第二和第三个目标，制定评估现有疫苗选择算法的有用性的标准，并确定关于组合疫苗决策的关键因素；评估现有疫苗算法的有用性，并衡量组合疫苗的益处和风险的社会价值。研究3将使用新获得的数据，对将常规流感疫苗接种扩大到所有年龄段的成本效益进行标准化估计。研究4将在疾控中心合作者的指导下确定。调查人员与环境。非常成功的JIVE项目是哈佛大学和疾控中心研究人员之间的合作，由疫苗经济学的全国领先者Tracy Lieu医学博士、Lisa Prosser博士和Grace Lee博士领导。现在该项目已经进入第六个年头，已经产生了许多对疫苗政策有很大影响的研究。研究计划。研究1将利用与儿科保健实践的半结构化访谈和现有研究的数据来估计联合疫苗的成本。研究2将包括(1)对各种利益相关者的定性访谈，以确定联合疫苗决策中的关键因素；(2)对代表美国人口的人进行基于互联网的调查。这项调查将包括一项离散选择实验，这是一种评估联合疫苗益处和风险价值的创新方法。在研究3中，我们将扩大现有的流感疫苗接种模式，以同时针对儿童和成人，并使用新获得的数据。创新和政策影响。该项目将为政策和方案决策提供关键信息。通过使用离散选择实验等创新，我们还将推动经济方法在医疗保健中的使用。需要对疫苗进行经济研究，以支持政府和其他关键方面做出明智的政策和规划决策。在这个项目中，我们将继续非常成功的疫苗经济学联合倡议，该倡议支持哈佛大学和疾病控制和预防中心的研究人员进行合作研究。我们将进行几项研究，包括评估与新的联合疫苗相关的成本和价值，以及将流感疫苗接种扩大到美国更多年龄段的成本效益。

DESCRIPTION (provided by applicant): Background. Vaccines are among the most cost-effective interventions in public health, but recently their costs have greatly increased. Ongoing vaccine economic research is needed to inform national policy recommendations, as well as programmatic choices by state immunization program managers, health insurers, and providers. Specific Aims. We request continued support of the Joint Initiative in Vaccine Economics (JIVE) Project, which supports research by Harvard and CDC investigators. We will conduct four studies. Study 1 will address the RFA's 1st objective, to estimate the costs associated with introducing combination vaccines into pediatric practices. Study 2 will address the RFA's 2nd and 3rd objectives, to develop criteria for assessing the usefulness of existing vaccine selection algorithms and identify key factors in decisions about combination vaccines; and to assess the usefulness of an existing vaccine algorithm and measure societal values for the benefits and risks of combination vaccines. Study 3 will use newly available data to generate standardized estimates of the cost-effectiveness of expanding routine influenza vaccination to all age groups. Study 4 will be determined with guidance from CDC collaborators. Investigators and Environment. The highly successful JIVE Project is a collaboration between Harvard and CDC investigators led by Tracy Lieu, MD, MPH, Lisa Prosser, PhD, and Grace Lee, MD, MPH, who are national leaders in vaccine economics. Now in its sixth year, the project has produced many studies with high impact on vaccine policy. Research Plan. Study 1 will estimate the costs of combination vaccines using semi- structured interviews with pediatric health care practices and data from existing studies. Study 2 will include (1) qualitative interviews with a variety of stakeholders to identify key factors in decisions on combination vaccines; and (2) an internet-based survey with persons representative of the U.S. population. The survey will include a discrete choice experiment, an innovative approach to estimating values for the benefits and risks of combination vaccines. In Study 3, we will expand an existing model on influenza vaccination to address both children and adults and to use newly available data. Innovation and Policy Implications. This project will generate crucial information for policy and programmatic decisions. By using innovations such as discrete choice experiments, we will also advance the use of economic methods in health care. Economic research on vaccines is needed to support informed policy and programmatic decisions by the government and other key parties. In this project we will continue the highly successful Joint Initiative in Vaccine Economics, which supports collaborative research by investigators at Harvard and the Centers for Disease Control and Prevention. We will conduct several studies, including evaluations of the costs and values associated with new combination vaccines and of the cost-effectiveness of expanding influenza vaccination to additional age groups in the United States.